Nano-Biological Contrast Agent Platform for MRI Imaging

Introduction

NANO-IMAGING proposes the elucidation of the potential of a metal-protein hybrid nanostructure as a platform for the development of tissue-specific positive Magnetic Resonance Imaging (MRI) contrast agents. This proposal builds on the large demand for MRI examinations worldwide, the health concerns raised by available contrast agents, and the little choice of tissue-specific contrast agents available to clinical practitioners.

Unique Value Proposition

The unique value proposition of NANO-IMAGING is a safe, bright, and tissue-specific MRI contrast agent. This is possible due to the purposely designed structure and composition of the nanostructure and the tissue-targeting properties thereof.

Proposed Solution

The proposed solution, based on proprietary technology, allows for the control of the nanomaterial properties and the straightforward customization of targeting moieties.

Having observed the basic principles of the technology, formulated the concept behind the idea, and conducted in-vitro experiments that prove the consistency of our revolutionary approach, we now want to further the technology towards clinical practice by testing it in-vivo.

Goals and Impact

By leveraging the platform nature of this solution and our capacity to tune the targeting properties of the nanostructure, we aim to provide a simple, tunable, and affordable development platform for the fabrication of biocompatible, tissue-specific MRI contrast agents à la carte.

Therefore, the successful outcome of this project will help realize the breakthrough and innovation potential of this solution for the fast and cost-effective development of a growing portfolio of tissue-specific MRI contrast agents. This will address a current societal challenge in health by satisfying the present demand for efficient, safe, and tissue-specific contrast agents for diagnosis.